Molecular Biology Reports

, Volume 40, Issue 2, pp 1827–1834

Genetic polymorphism of interleukin 1β −511C/T and susceptibility to sporadic Alzheimer’s disease: a meta-analysis

Article

Abstract

A large number of epidemiological studies have been performed to investigate the association between Alzheimer’s disease (AD) risk and interleukin-1β −511C/T genetic polymorphism, however, inconsistent results have been reported. The effect of the IL-1β −511C/T polymorphism on AD susceptibility was evaluated by a meta-analysis. Series of databases were researched. 14 studies involving 2640 AD case and 3493 control subjects were identified. The pooled results showed there were no statistical associations of interleukin-1β −511C/T genetic polymorphism with susceptibility to AD for five analysis models in all subjects. However, obvious heterogeneity among studies was detected. When stratifying for age at onset, ethnicity and geographic distribution of population to explore the original source of heterogeneity, the meta-analysis results based on geographic distribution of population showed the significant difference (CC vs CT, OR 1.26, 95 % CI: 1.03, 1.54, z = 2.25, P = 0.025; CC vs CT+TT, OR 1.24, 95 % CI: 1.03, 1.50, z = 2.24, P = 0.025) only in non-Europe. These findings indicate that the IL-1β −511C/T polymorphism might be associated with AD risk, and individuals with IL-1β −511C/C genotype might be at higher risk of AD in non-Europe. Further larger sample research would be warranted to confirm these conclusions.

Keywords

Interleukin 1β Alzheimer’s disease Polymorphism Meta-analysis 

References

  1. 1.
    McGeer EG, McGeer PL (1998) The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 33:371–378PubMedCrossRefGoogle Scholar
  2. 2.
    Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrak RE (1998) Glial-neuronal interactions in Alzheimer’s disease: the potential role of a cytokine cycle in disease progression. Brain Pathol 8:65–72PubMedCrossRefGoogle Scholar
  3. 3.
    Sheng JG, Mrak RE, Griffin WS (1997) Glial-neuronal interactions in Alzheimer’s disease: progressive association of IL-1a microglia and S100b astrocytes with neurofibrillary tangle stages. J Neuropathol Exp Neurol 56:285–290PubMedCrossRefGoogle Scholar
  4. 4.
    Sheng JG, Mrak RE, Griffin WS (1995) Microglial interleukin-1a expression in brain regions in Alzheimer’s disease: correlation with neuritic plaque distribution. Neuropath Appl Neurol 21:290–301CrossRefGoogle Scholar
  5. 5.
    Cacabelos R, Barquero M, García P, Alvarez XA, Varela de Seijas E (1991) Cerebrospinal fluid interleukin-1beta (IL-1 beta) in Alzheimer’s disease and neurological disorders. Methods Find Exp Clin Pharmacol 13:455–458PubMedGoogle Scholar
  6. 6.
    Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 86:7611–7615PubMedCrossRefGoogle Scholar
  7. 7.
    Dinarello CA (1996) Biological basis for interleukin 1 in disease. Blood 87:2095–2147PubMedGoogle Scholar
  8. 8.
    Mattila KM, Rinne JO, Lehtimaki T, Roytta M, Ahonen JP, Hurme M (2002) Association of an interleukin 1B gene polymorphism (−511) with Parkinson’s disease in Finnish patients. J Med Genet 39:400–402PubMedCrossRefGoogle Scholar
  9. 9.
    Grimaldi LME, Casadei VM, Ferri C, Veglia F, Licastro F, Annoni G, Biunno I, De-Bellis G, Sorbi S, Mariani C, Canal N, Griffin WST, Franceschi M (2000) Association of early-onset Alzheimer’s disease with an interleukin-1a gene polymorphism. Ann Neurol 47:361–365PubMedCrossRefGoogle Scholar
  10. 10.
    Minster RL, Dekosky ST, Ganguli M, Belle S, Kamboh MI (2000) Genetic association studies of interleukin-1 (IL-1A and IL-1B) and interleukin-1 receptor antagonist genes and the risk of Alzheimer’s disease. Ann Neurol 48:817–819PubMedCrossRefGoogle Scholar
  11. 11.
    Green EK, Harris JM, Lemmon H, Lambert JC, Chartier-Harlin MC, St Clair D, Mann DM, Iwatsubo T, Lendon CL (2002) Are interleukin-1 gene polymorphisms risk factors or disease modifiers in AD? Neurology 58:1566–1568PubMedCrossRefGoogle Scholar
  12. 12.
    Licastro F, Pedrini S, Ferri C, Casadei V, Govoni M, Pession A, Sciacca FL, Veglia F, Annoni G, Bonafè M, Olivieri F, Franceschi C, Grimaldi LM (2000) Gene polymorphism affecting alpha1-antichymotrypsin and interleukin-1 plasma levels increases Alzheimer’s disease risk. Ann Neurol 48:388–391PubMedCrossRefGoogle Scholar
  13. 13.
    Licastro F, Porcellini E, Caruso C, Lio D, Corder EH (2007) Genetic risk profiles for Alzheimer’s disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 28:1637–1643PubMedCrossRefGoogle Scholar
  14. 14.
    Bertram L, Blacker D, Crystal A, Mullin K, Keeney D, Jones J, Basu S, Yhu S, Guénette S, McInnis M, Go R, Tanzi R (2000) Candidate genes showing no evidence for association or linkage with Alzheimer’s disease using family-based methodologies. Exp Gerontol 35:1353–1361PubMedCrossRefGoogle Scholar
  15. 15.
    Schjeide BM, McQueen MB, Mullin K, Divito J, Hogan MF, Parkinson M, Hooli B, Lange C, Blacker D, Tanzi RE, Bertram L (2009) Assessment of Alzheimer’s disease case-control associations using family-based methods. Neurogenetics 10:19–25PubMedCrossRefGoogle Scholar
  16. 16.
    Giedraitis V, Kilander L, Degerman-Gunnarsson M, Sundelöf J, Axelsson T, Syvänen AC, Lannfelt L, Glaser A (2009) Genetic analysis of Alzheimer’s disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord 27:59–68PubMedCrossRefGoogle Scholar
  17. 17.
    Rosenmann H, Meiner Z, Dresner-Pollak R, Kahana E, Aladjem Z, Grenader T, Wertman E, Abramsky O (2004) Lack of association of interleukin-1beta polymorphism with Alzheimer’s disease in the Jewish population. Neurosci Lett 363:131–133PubMedCrossRefGoogle Scholar
  18. 18.
    Sciacca FL, Ferri C, Licastro F, Veglia F, Biunno I, Gavazzi A, Calabrese E, Martinelli Boneschi F, Sorbi S, Mariani C, Franceschi M, Grimaldi LM (2003) Interleukin-1B polymorphism is associated with age at onset of Alzheimer’s disease. Neurobiol Aging 24:927–931PubMedCrossRefGoogle Scholar
  19. 19.
    Nicoll JA, Mrak RE, Graham DI, Stewart J, Wilcock G, MacGowan S, Esiri MM, Murray LS, Dewar D, Love S, Moss T, Griffin WS (2000) Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 47:365–368PubMedCrossRefGoogle Scholar
  20. 20.
    Oliveira JR, Nishimura AL, Lemos RR, Zatz M (2009) The genetics of Alzheimer’s disease in Brazil: 10 years of analysis in a unique population. J Mol Neurosci 37:74–79PubMedCrossRefGoogle Scholar
  21. 21.
    Hedley R, Hallmayer J, Groth DM, Brooks WS, Gandy SE, Martins RN (2002) Association of interleukin-1 polymorphisms with Alzheimer’s disease in Australia. Ann Neurol 51:795–797PubMedCrossRefGoogle Scholar
  22. 22.
    Ehl C, Kölsch H, Ptok U, Jessen F, Schmitz S, Frahnert C, Schlösser R, Rao ML, Maier W, Heun R (2003) Association of an interleukin-1beta gene polymorphism at position −511 with Alzheimer’s disease. Int J Mol Med 11:235–238PubMedGoogle Scholar
  23. 23.
    Wang WF, Liao YC, Wu SL, Tsai FJ, Lee CC, Hua CS (2005) Association of interleukin-I beta and receptor antagonist gene polymorphisms with late onset Alzheimer’s disease in Taiwan Chinese. Eur J Neurol 12:609–613PubMedCrossRefGoogle Scholar
  24. 24.
    Ravaglia G, Paola F, Maioli F, Martelli M, Montesi F, Bastagli L, Bianchin M, Chiappelli M, Tumini E, Bolondi L, Licastro F (2006) Interleukin-1b and interleukin-6 gene polymorphisms as risk factors for AD: a prospective study. Exp Gerontol 41:85–92PubMedCrossRefGoogle Scholar
  25. 25.
    Wang HK, Hsu WC, Fung HC, Lin JC, Hsu HP, Wu YR, Hsu Y, Hu FJ, Lee-Chen GJ, Chen CM (2007) Interleukin-1a and -1b promoter polymorphisms in Taiwanese patients with dementia. Dement Geriatr Cogn Disord 24:104–110PubMedCrossRefGoogle Scholar
  26. 26.
    Déniz-Naranjo MC, Muñoz-Fernandez C, Alemany-Rodríguez MJ, Pérez-Vieitez MC, Aladro-Benito Y, Irurita-Latasa J, Sánchez-García F (2008) Cytokine IL-1beta but not IL-1alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. Eur J Neurol 15:1080–1084PubMedCrossRefGoogle Scholar
  27. 27.
    Klimkowicz-Mrowiec A, Marona M, Wołkow P, Maruszak A, Styczynska M, Barcikowska M, Zekanowski C, Szczudlik A, Slowik A (2009) Interleukin-1 gene –511CT polymorphism and the risk of Alzheimer’s disease in a polish population. Dement Geriatr Cogn Disord 28:461–464PubMedCrossRefGoogle Scholar
  28. 28.
    Wehr H, Bednarska-Makaruk M, Łojkowska W, Graban A, Hoffman-Zacharska D, Kuczyńska-Zardzewiały A, Mrugała J, Rodo M, Bochyńska A, Sułek A, Ryglewicz D (2006) Differences in risk factors for dementia with neurodegenerative traits and for vascular dementia. Dement Geriatr Cogn Disord 22:1–7PubMedCrossRefGoogle Scholar
  29. 29.
    McCulley MC, Day IN, Holmes C (2004) Association between interleukin 1-beta promoter (−511) polymorphism and depressive symptoms in Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 124B:50–53PubMedCrossRefGoogle Scholar
  30. 30.
    Ma SL, Tang NL, Lam LC, Chiu HF (2003) Lack of association of the interleukin-1b gene polymorphism with Alzheimer’s disease in a Chinese population. Dement Geriatr Cogn Disord 16:265–268PubMedCrossRefGoogle Scholar
  31. 31.
    Bosco P, Guéant-Rodríguez RM, Anello G, Romano A, Namour B, Spada RS, Caraci F, Tringali G, Ferri R, Guéant JL (2004) Association of IL-1 RN*2 allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer’s disease. J Neurol Neurosurg Psychiatry 75:1036–1038PubMedCrossRefGoogle Scholar
  32. 32.
    Yucesoy B, Peila R, White LR, Wu KM, Johnson VJ, Kashon ML, Luster MI, Launer LJ (2006) Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: the Honolulu-Asia aging study. Neurobiol Aging 27:211–217PubMedCrossRefGoogle Scholar
  33. 33.
    Li XQ, Zhang JW, Zhang ZX, Chen D, Qu QM (2004) Interleukin-1 gene cluster polymorphisms and risk of Alzheimer’s disease in Chinese Han population. J Neural Transm 111:1183–1190PubMedCrossRefGoogle Scholar
  34. 34.
    Nishimura M, Sakamoto T, Kaji R, Kawakami H (2004) Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer’s disease. Neurosci Lett 368:140–143PubMedCrossRefGoogle Scholar
  35. 35.
    Seripa D, Matera MG, Dal Forno G, Gravina C, Masullo C, Daniele A, Binetti G, Bonvicini C, Squitti R, Palermo MT, Davis DG, Antuono P, Wekstein DR, Dobrina A, Gennarelli M, Fazio VM (2005) Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients. Neurobiol Aging 26:455–464PubMedCrossRefGoogle Scholar
  36. 36.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-A DRDA work group under the auspices of department of health and human services task force on alzheimer’s disease. Neurology 34:939–944PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Department of Rehabilitation MedicineThe Second People’s Hospital of Hefei CityHefeiChina

Personalised recommendations